FDA approves Astra Zeneca, Merck & Co. drug

Monday, 30. December 2019 10:13

American pharmaceutical giants AstraZeneca and Merck & Co. Inc. announced on Monday that Lynparza or olaparib has been approved in the United States for the treatment of adult patients with germline BRCA-mutated pancreatic cancer.

The drug, which acts as a PARP inhibitor that blocks further DNA damage in cells, is the only one of its kind that has been approved in the treatment of the said type of cancer. Lynparza is also being used to treat advanced ovarian cancer and metastatic breast cancer and has been used in over 25,000 patients worldwide.

AstraZeneca and Merck & Co. Inc. have been working on the trial testing of Lynparza for some time.

Shares of AstraZeneca traded 0.21% lower at 9:58 am CET.

Related Links: Merck & Co. Inc.AstraZeneca plcAstraZeneca plc
Breaking the News / DD